Role of Toll-like receptor responses for sepsis pathogenesis

Immunobiology

Volumn 212, Issue 9-10, 2008, Pages 715-722

  Weighardt, Heike ^a,b   Holzmann, Bernhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Gene polymorphism; Innate immunity; Sepsis; Toll like receptors; Type I interferons

Indexed keywords

BETA INTERFERON; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

ARTICLE; BACTERIAL INFECTION; CYTOKINE PRODUCTION; DISEASE MODEL; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

EID: 37049024099     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2007.09.010     Document Type: Article

References (91)

1. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., Nakanishi K., and Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9 (1998) 143-150
2. Agnese D.M., Calvano J.E., Hahm S.J., Coyle S.M., Calvano S.E., and Lowry S.F. Human Toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J. Infect. Dis. 186 (2002) 1522-1525
3. An H., Zhao W., Hou J., Zhang Y., Xie Y., Zheng Y., Xu H., Qian C., Zhou J., Yu Y., Liu S., Feng G., and Cao X. SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type-I interferon and proinflammatory cytokine production. Immunity 25 (2006) 919-928
4. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., Fress K., Watt J.L., and Schwartz D.A. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25 (2000) 187-191
5. Auerbuch V., Brockstedt D.G., Meyer-Morse N., O'Riordan M., and Portnoy D.A. Mice lacking the Type-I interferon receptor are resistant to Listeria monocytogenes. J. Exp. Med. 200 (2004) 527-533
6. Bernard G.R., Vincent J.-L., Laterre P.F., LaRosa S.P., Dhainaut J.-F., Lopez-Rodriguez A., Steingrub J.S., Garber G.E., Helterbrand J.D., Ely E.W., and Fisher C.J. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344 (2001) 699-709
7. Beutler B. Innate immunity: an overview. Mol. Immunol. 40 (2004) 854-859
8. Beutler B., Hoebe K., Georgel P., Tabeta K., and Du X. Genetic analysis of innate immunity: identification and function of the TIR adapter proteins. Adv. Exp. Med. Biol. 560 (2005) 29-39
9. Biron C.A. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin. Immunol. 10 (1998) 1109-1121
10. Bogdan C., Mattner J., and Schleicher U. The role of Type-I interferons in non-viral infections. Immunol. Rev. 202 (2004) 33-48
11. Bone R.C. Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS). J. Am. Med. Assoc. 273 (1995) 155-156
12. Brint E.K., Xu D., Liu H., Dunne A., McKenzie A.N.J., O'Neill L.A.J., and Liew F.Y. ST2 is an inhibitor of interleukin-1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 5 (2004) 373-379
13. Buras J.A., Holzmann B., and Sitkkowsky M. Animal models of sepsis: setting the stage. Nat. Rev. Drug Discov. 4 (2005) 854-865
14. Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., and Tschopp J. Inhibition of interleukin-1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197 (2003) 263-268
15. Carrero J.A., Calderon B., and Unanue E.R. Type-I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J. Exp. Med. 200 (2004) 535-540
16. Carty M., Goodbody R., Schroder M., Stack J., Moynagh P.N., and Bowie A.G. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat. Immunol. 7 (2006) 1023-1025
17. Choi K.C., Lee Y.S., Lim S., Choi H.K., Lee C.H., Lee E.K., Hong S., Kim I.H., Kim S.J., and Park S.H. Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor signaling through direct interaction with the adaptor Pellino-1. Nat. Immunol. 7 (2006) 1057-1065
18. Chuang T.-H., and Ulevitch R.J. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat. Immunol. 5 (2004) 495-502
19. Decker T., Stockinger S., Karaghiosoff M., Müller M., and Kovarik P. IFNs and STATs in innate immunity to microorganisms. J. Clin. Invest. 109 (2002) 1271-1277
20. Diefenbach A., Schindler H., Donhauser N., Lorenz E., Laskay T., MacMicking J., Röllinghoff M., Gresser I., and Bogdan C. Type-1 interferon (IFNα/β) and type-2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity 8 (1998) 77-87
21. Divanovic S., Trompette A., Atabani S.F., Madan R., Golenbock D.T., Visintin A., Finberg R.W., Tarakhovsky A., Vogel S.N., Belkaid Y., Kurt-Jones E.A., and Karp C.L. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat. Immunol. 6 (2005) 571-578
22. Echtenacher B., Freudenberg M.A., Jack R.S., and Männel D.N. Differences in innate defense mechanisms in endotoxemia and polymicrobial peritonitis. Infect. Immun. 69 (2001) 7271-7276
23. Feterowski C., Emmanuilidis K., Miethke T., Gerauer K., Rump M., Ulm K., Holzmann B., and Weighardt H. Effects of functional Toll-like receptor-4 mutations in the immune response to human and experimental sepsis. Immunology 109 (2003) 426-431
24. Feterowski C., Mack M., Weighardt H., Bartsch B., Kaiser-Moore S., and Holzmann B. CC chemokine receptor 2 regulates leukocyte recruitment and 10 production during acute polymicrobial sepsis. Eur. J. Immunol. 34 (2004) 3664-3673
25. Fitzgerald K.A., Rowe D.C., Barnes B.J., Caffrey D.R., Visintin A., Latz E., Monks B., Pitha P.M., and Golenbock D.T. LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the Toll adapters TRAM and TRIF. J. Exp. Med. 198 (2003) 1043-1055
26. Han K.-J., Su X., Xu L.-G., Bin L.-H., Zhang J., and Shu H.-B. Mechanisms of the TRIF-induced interferon-stimulated response element and NF-κB activation and apoptosis pathways. J. Biol. Chem. 279 (2004) 15652-15661
27. Hardy M.P., and O'Neill L.A. The murine IRAK2 gene encodes four alternatively spliced isoforms, two of which are inhibitory. J. Biol. Chem. 279 (2004) 27699-27708
28. Hawn T.R., Verbon A., Lettinga K.D., Zhao L.P., Li S.S., Laws R.J., Skerrett S.J., Beutler B., Schroeder L., Nachmann A., Ozinsky A., Smith K.D., and Aderem A. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J. Exp. Med. 198 (2003) 1563-1572
29. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., and Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
30. Hoebe K., Du X., Goergel P., Janssen E., Tabeta K., Kim S.O., Goode J., Lin P., Mann N., Mudd S., Crozat K., Sovath S., Han J., and Beutler B. Identification of Lps2 as a key transducer of MyD88-independent TIR signaling. Nature 424 (2003) 743-748
31. Hoebe K., Janssen E.M., Kim S.O., Alexopoulou L., Flavell R.A., Han J., and Beutler B. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat. Immunol. 4 (2003) 1223-1229
32. Honma K., Udono H., Kohno T., Yamamoto K., Ogawa A., Takemori T., Kumatori A., Suzuki S., Matsuyama T., and Yui K. Interferon regulatory factor 4 negatively regulates the production of proinflammatory cytokines by macrophages in response to LPS. Proc. Natl. Acad. Sci. USA 102 (2005) 16001-16006
33. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., Takeda K., and Akira S. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the lps gene product. J. Immunol. 162 (1999) 3749-3752
34. Hoshino K., Kaisho T., Iwabe T., Takeuchi O., and Akira S. Differential involvement of IFN-β in Toll-like receptor-stimulated dendritic cell activation. Int. Immunol. 14 (2002) 1225-1231
35. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348 (2003) 138-150
36. Hubbard W.J., Choudhry M., Schwacha M.G., Kerby J.D., Rue III L.W., Bland K.I., and Chaudry I.H. Cecal ligation and puncture. Shock 24 (2005) 52-57
37. Imahara S.D., and O'Keefe G.E. Genetic determinants of the inflammatory response. Curr. Opin. Crit. Care 10 (2004) 318-324
38. Janssens S., Burns K., Vercammen E., Tsay H.C., and Beyaert R. MyD88S, a splice variant of MyD88, differentially modulates NF-kappaB- and AP-1-dependent gene expression. FEBS Lett. 548 (2003) 103-107
39. Kang T.J., Lee S.B., and Chae G.T. A polymorphism in the Toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine 20 (2002) 56-62
40. Karaghiosoff M., Steinborn R., Kovarik P., Kriegshäuser G., Baccarini M., Donabauer B., Reichart U., Kolbe T., Bogdan C., Leanderson T., Levy D., Decker T., and Müller M. Central role for type-I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol. 4 (2003) 471-477
41. Kawai T., Adachi O., Ogawa T., Takeda K., and Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11 (1999) 115-122
42. Kawai T., Sato S., Ishii K.J., Coban C., Hemmi H., Yamamoto M., Terai K., Matsuda M., Inoue J., Uematsu S., Takeuchi O., and Akira S. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5 (2004) 1061-1086
43. Kawai T., and Akira S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17 (2005) 338-344
44. Kobayashi K., Hernandez L.D., Galán J.E., Janeway C.A., Medzhitov R., and Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110 (2002) 191-202
45. Kumpf O., Hamann L., Schlag P.M., and Schumann R.R. Pre-and postoperative cytokine release after in vitro whole blood lipopolysaccharide stimulation and frequent Toll-like receptor polymorphism. Shock 25 (2006) 123-1128
46. Kurt-Jones E.A., Popova L., Kwinn L., Haynes L.M., Jones L.P., Tripp R.A., Walsh E.E., Freeman M.W., and Golenbock D.T. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1 (2000) 398-401
47. Li S., Strelow A., Fontana E.J., and Wesche H. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc. Natl. Acad. Sci. USA 99 (2002) 5567-5572
48. Lorenz E., Mira J.-P., Cornish K.L., Arbour N.C., and Schwartz D.A. A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect. Immun. 68 (2000) 6398-6401
49. Lorenz E., Mira J.P., Frees K.L., and Schwartz D.A. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 162 (2002) 1028-1032
50. Malhotra D., Relhan V., Reddy B.S., and Bamezai R. TLR2 Arg677Trp polymorphism in leprosy: revisited. Hum. Genet. 116 (2005) 413-415
51. Matsumoto M., Funami K., Oshiumi H., and Seya T. Toll-like receptor 3: a link between Toll-like receptor, interferon and viruses. Microbiol. Immunol. 48 (2004) 147-154
52. Medvedev A.E., Lentschat A., Kuhns D.B., Blanco J.C.G., Salkowski C., Zhang S., Arditi M., Gallin J.I., and Vogel S.N. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198 (2003) 521-531
53. Medzhitov R., Preston-Hurlburt P., Kopp E., Stadlen A., Chen C., Ghosh S., and Janeway C.A. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 2 (1998) 253-258
54. Meng G., Rutz M., Schiemann M., Metzger J., Grabiec A., Schwandner R., Luppa P.B., Ebel F., Busch D.H., Bauer S., Wagner H., and Kirschning C.J. Antagonistic antibody prevents Toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invest. 113 (2004) 1473-1481
55. Muzio M., Ni J., Feng P., and Dixit V.M. IRAK (pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278 (1997) 1612-1615
56. Negishi H., Ohba Y., Yanai H., Takaoka A., Honma K., Yui K., Matsuyama T., Taniguchi T., and Honda K. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc. Natl. Acad. Sci. USA 102 (2005) 15989-15994
57. Ogus A.C., Yoldas B., Ozdemir T., Uguz A., Olcen S., Keser I., Coskun M., and Cilli A. The Arg753GLn polymorphism of the human Toll-like receptor 2 gene in tuberculosis disease. Eur. Respir. J. 23 (2006) 219-223
58. Oshiumi H., Matsumoto M., Funami K., Akazawa T., and Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat. Immunol. 4 (2003) 161-167
59. O'Connell R.M., Saha S.K., Vaidya S.A., Bruhn K., Miranda G.A., Zarnegar B., Perry A.K., Nguyen B.O., Lane T.F., Taniguchi T., Miller J.F., and Cheng G. Type-I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med. 200 (2004) 437-445
60. Picard C., Puel A., Bonnet M., Ku C.-L., Bustamante J., Yang K., Soudais C., Dupuis S., Feinberg J., Fieschi C., Elbim C., Hitchcock R., Lammas D., Davies G., Al-Ghonaium A., Al-Rayes H., Al-Jumaah S., Al-Hajjar S., Al-Mohsen I.Z., Frayha H.H., Rucker R., Hawn T.R., Aderem A., Tufenkeji H., Haraguchi S., Day N.K., Good R.A., Gougerot-Pocidalo M.-A., Ozinsky A., and Casanova J.-L. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299 (2003) 2076-2079
61. Poltorak A., He X., Smirnova I., Liu M.-Y., van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., and Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998) 2085-2088
62. Qin J., Qian Y., Yao J., Grace C., and Li X. SIGIRR inhibits interleukin-1 receptor- and Toll-like receptor 4-mediated signaling through different mechanisms. J. Biol. Chem. 80 (2005) 25233-25241
63. Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K., and Akira S. Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-κB and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 171 (2003) 4304-4310
64. Schröder N.J., Ditterich I., Zinke A., Eckert J., Draing C., von Baer V., Hassler S., Priem S., Hahn K., Michelsen K.S., Hartung T., Burmeister G.R., Göbel U.B., Hermann C., and Schumann R.R. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borellia burgdorferi and protects from late stage Lyme disease. J. Immunol. 175 (2005) 2534-2540
65. Sirén J., Pirhonen J., Julkunen I., and Matikainen S. IFN-α regulates TLR-dependent gene expression of IFN-α, IFN-β, IL-28, and IL-29. J. Immunol. 174 (2005) 1932-1937
66. Smirnova, I., Poltorak, A., Chan, E.K.L., McBride, C., Beutler, B., 2000. Phylogenetic variation and polymorphism at the Toll-like receptor 4 locus (TLR4). Genome Biol. 1, research002.1-002.10.
67. Smirnova I., Mann N., Dols A., Derkx H.H., Hibberd M.L., Levin M., and Beutler B. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc. Natl. Acad. Sci. USA 100 (2003) 6075-6080
68. Suzuki N., Suzuki S., Duncan G.S., Millar D.G., Wada T., Mirtos C., Takada H., Wakeham A., Itie A., Li S., Penninger J.M., Wesche H., Ohashi P.S., Mak T.W., and Yeh W.-C. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416 (2002) 750-754
69. Swantek J.L., Tsen M.F., Cobb M.H., and Thomas J.A. IL-1 receptor-associated kinase modulates host responsiveness to endotoxin. J. Immunol. 164 (2000) 4301-4306
70. Takaesu G., Kishida S., Hiyama A., Yamaguchi K., Shibuya H., Irie K., Ninomiya-Tsuji J., and Matsumoto A. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell. 4 (2000) 649-658
71. Takakuwa T., Knopf H.P., Sing A., Carsetti R., Galanos C., and Freudenberg M.A. Induction of CD14 expression in Lpsn, Lpsd and tumor necrosis factor receptor-deficient mice. Eur. J. Immunol. 26 (1996) 2686-2692
72. Takeda K., and Akira S. TLR signaling pathways. Semin. Immunol. 16 (2004) 3-9
73. Takeuchi O., Takeda K., Hoshino K., Adachi O., Ogawa T., and Akira S. Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int. Immunol. 12 (2000) 113-117
74. Theofilopoulus A.N., Baccala R., Beutler B., and Kono D.H. Type-I interferons (α/β) in immunity and autoimmunity. Annu. Rev. Immunol. 23 (2005) 307-336
75. Thomassen E., Renshaw B.R., and Sims J.E. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 11 (1999) 389-399
76. van den Broek M.F., Muller U., Huang S., Zinkernagel R., and Aguet M. Immune defence in mice lacking type-I and/or type-II interferon receptors. Immunol. Rev. 148 (1995) 5-18
77. van der Poll T. Immunotherapy of sepsis. Lancet Inf. Dis. 1 (2001) 165-174
78. van der Poll T., and Deventer S.J. Cytokines and anticytokines in the pathogenesis of sepsis. Infect. Dis. Clin. North Am. 13 (1999) 413-426
79. van Deventer S. Antibody to endotoxin in the treatment of gram-negative sepsis. J. Am. Med. Assoc. 267 (1992) 2325-2326
80. Weigent D.A., Huff T.L., Peterson J.W., Stanton G.J., and Baron S. Role of interferon in streptococcal infection in the mouse. Microb. Pathog. 1 (1986) 399-407
81. Weighardt H., Kaiser-Moore S., Vabulas R.M., Kirschning C., Wagner H., and Holzmann B. Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J. Immunol. 169 (2002) 2823-2827
82. Weighardt H., Jusek G., Mages J., Lang R., Hoebe K., Beutler B., and Holzmann B. Identification of a TLR4- and TRIF-dependent activation program of dendritic cells. Eur. J. Immunol. 34 (2004) 558-564
83. Weighardt H., Kaiser-Moore S., Schlautkötter S., Rossmann-Bloeck T., and Holzmann B. Type-I IFN modulates host defense and late hyper-inflammation in septic peritonitis. J. Immunol. 177 (2006) 5623-5630
84. Weighardt H., Mages J., Jusek G., Kaiser-Moore S., Lang R., and Holzmann B. Organ-specific role of MyD88 for gene regulation during polymicrobial peritonitis. Infect. Immun. 74 (2006) 3618-3632
85. Wesche H., Henzel W.J., Shillinglaw W., Li S., and Cao Z. MyD88: an adpater that recruits IRAK to the IL-1 receptor complex. Immunity 7 (1997) 837-847
86. Wichterman K.A., Baue A.E., and Chaudry I.H. Sepsis and septic shock - a review of laboratory models and a proposal. J. Surg. Res. 29 (1980) 189-201
87. Yamamoto M., Sato S., Mori K., Hoshino K., Takeuchi O., Takeda K., and Akira S. A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J. Immunol. 169 (2002) 6668-6672
88. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., Takeuchi O., Sugiyama M., Okabe M., Takeda K., and Akira S. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301 (2003) 640-643
89. Yamamoto M., Sato S., Hemmi H., Uematsu S., Hoshino K., Kaisho T., Takeuchi O., Takeda K., and Akira S. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol. 4 (2003) 1144-1150
90. Zantl N., Uebe A., Neumann B., Wagner H., Siewert J.R., Holzmann B., Heidecke C.D., and Pfeffer K. Essential role of γ-interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect. Immun. 66 (1998) 2300-2309
91. Zhang G., and Ghosh S. Negative regulation of Toll-like receptor-mediated signaling by Tollip. J. Biol. Chem. 277 (2002) 7059-7065